Codexis Presents Pre-Clinical Data Highlighting its Programs in Homocystinuria and Maple Syrup Urine Disease at ICIEM 2021
22 nov. 2021 08h00 HE
|
Codexis, Inc.
REDWOOD CITY, Calif., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that two of the...
Codexis to Participate in Upcoming Virtual Healthcare Conferences
19 nov. 2021 08h00 HE
|
Codexis, Inc.
REDWOOD CITY, Calif., Nov. 19, 2021 (GLOBE NEWSWIRE) -- Codexis, inc. (Nasdaq:CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that management...
Codexis Appoints Two New Senior Leaders for Human Resources and Corporate Development
15 nov. 2021 08h00 HE
|
Codexis, Inc.
REDWOOD CITY, Calif., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced the appointments...
Codexis to Present Data Highlighting Two New Therapeutic Discovery Programs at the 14th International Congress of Inborn Errors of Metabolism 2021
15 nov. 2021 08h00 HE
|
Codexis, Inc.
REDWOOD CITY, Calif., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Codexis, inc. (Nasdaq:CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced two oral...
Codexis to Participate in Upcoming Virtual Healthcare Conferences
09 nov. 2021 16h05 HE
|
Codexis, Inc.
REDWOOD CITY, Calif., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq:CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that management...
Codexis Reports Third Quarter 2021 Financial Results
04 nov. 2021 16h05 HE
|
Codexis, Inc.
Record Quarterly Total Revenue, Product Revenue and Product Gross MarginReiterating Total Revenue Guidance of $98-103M; Raising Product Revenue Guidance to $63-66M REDWOOD CITY Calif., Nov. 04,...
The SynBio Innovation Accelerator, a Collaboration between Codexis and Casdin Capital, Enables $10 million Investment in Molecular Assemblies, Inc.
04 nov. 2021 08h00 HE
|
Codexis, Inc.
Funding to accelerate MAI’s go-to-market strategy as the enzyme engineering phase nears completion Represents the second early-stage company investment enabled by the SynBio Innovation Accelerator ...
Codexis and Nestlé Health Science Initiate a Phase 1 Clinical Trial of CDX-7108 for Exocrine Pancreatic Insufficiency
03 nov. 2021 16h05 HE
|
Codexis, Inc.
REDWOOD CITY, Calif., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company and developer of novel biotherapeutics, and Nestlé Health Science, a...
Codexis to Report Third Quarter 2021 Financial Results on November 4
21 oct. 2021 16h05 HE
|
Codexis, Inc.
REDWOOD CITY, Calif., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq:CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that it will...
Codexis, Almelo and RC2 Announce a Tri-Party Collaboration for the Enzymatic Production of Low Cost Sitagliptin API for the Generic Market, Including a License to Codexis Enzyme Technology in India
18 oct. 2021 08h00 HE
|
Codexis, Inc.
REDWOOD CITY, Calif., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, announced a tri-party...